We are proud to announce that our affiliate partner Biomimetic Innovations Limited(BMI), has announced the execution of an exclusive license and distribution agreement with Sanara MedTech Inc. Sanara agreed to invest in BMI with cash for equity at the same time. Sanara, a medical technology company based in Fort Worth, Texas, with attention to developing and commercializing cutting-edge technologies to improve clinical outcomes and reduce expenses for healthcare in the chronic wound, surgical and skincare markets. Sanara now has the exclusive U.S. marketing, sales, and distribution rights to OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler (“OsStic®”) under the terms of the License and Distribution Agreement, as well as a hardware adaptable supplementary internal fixation technology featuring a newly to promote targeted application of OsStic®, for use in fracture management. The License and Distribution Agreement is for an initial five-year period, with the option to automatically renew for another two years at the discretion of Sanara. Developed by Biomimetic Innovations Ltd, OsStic®, is a disruptive new bio-adhesive bone void filler technology which was granted a Breakthrough Device Designation by the U.S. Food and Drug Administration (“FDA”) on December 10, 2023. The proposed indication statement for OsStic® is [a] “structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of periarticular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional mobilization.” Breakthrough Device Designation is granted to medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions. “We are excited to announce this strategic agreement and investment in Biomimetic Innovations,” said Ron Nixon, Sanara’s Executive Chairman and CEO. “OsStic® offers a truly differentiated solution, designed to enhance the fracture repair process. We believe OsStic® represents a compelling treatment option for the more than 100,000 periarticular fractures that occur in the U.S. annually.” Dr. Thomas Russell, Chief Medical Officer of PBC Biomed (an affiliate of BMI), stated, “Unlike conventional materials, OsStic® is engineered to optimize fluidic dispersion into bone defects, interdigitate with the surrounding boney structure, and firmly adhere to bone surfaces. These properties provide exceptional structural integrity and mechanically enhanced bioadhesion, making OsStic® uniquely suited for reducing periarticular fractures, achieving provisional fixation, and filling voids. As the first calcium phosphate-based synthetic technology to address all three critical clinical needs, OsStic® offers an unparalleled solution for preserving joint congruency and improving patient outcomes.” Managing Partner of PBC Biomed Ltd and the acting CEO of Biomimetic Innovations, Paul Burke, stated, “Our goal is to ‘enhance patient wellness’ using disruptive medical innovations. With its market expertise, sales and distribution network, and existing customer relationships, Sanara represents an ideal partner to commercialize our innovative technologies. Together, we look forward to bringing transformative solutions to market that enhance the surgeon’s treatment approach and improve patient outcomes.” #bioadhesive #Bio-Adhesive #biomaterials #biomimetcinnovations #breakthroughDesignation #medtech #partnership #sanara #innovation

PBC Biomed are ready for action at the Orthopaedic Trauma Association meeting in Montreal! Stop by booth #431 to meet our team and learn more about our new #innovations, powered by our Accelerating Innovation Model ‘AIM’. #acceleratingmedicalinnovation #biomaterials #newinnovations

We are delighted to introduce our new company video, created by Christian Gyalus at Éalú Media. This video provides a fantastic insight into our mission, to enhance patient wellbeing by accelerating medical innovation; as well as the work that we do to achieve this mission. Huge thank you to Christian for making our vision a reality, and to the team for their support and contribution. We are thrilled with the end result! #pbcbiomed #acceleraratingmedicalinnovation #mission

PBC Biomed has partnered with local universities to run several successful internship and co-operative programmes over the last number of years. Subsequently, we have been lucky to welcome many talented new graduates and early-stage career professionals to our team! They have brought curiosity, enthusiasm, new ideas and ways of doing things to our business, which is critical in helping us to drive hashtag#innovation and achieve our mission of enhancing patient wellbeing. If you or someone you know has an interest in learning more about the industry or gaining some industry experience, please contact us at [email protected] #acceleratingmedicalinnovation #newgraduates #medicaldevices

One of the benefits of being a hashtag#global company is that we can be two places at the same time! Pictured at the #ESTROT event in Helsinki this week are Product Manager Bronagh O’Doherty and R&D Engineer Antzela Tzagiollari. Thank you to the society for a warm welcome to this year’s event and for a fantastic three days of education, discussion and presentations. Meantime, representatives from our Business Development team Brittney Martinez and David Sharp, our Operations team Eoghan Burke, and our Clinical Research team Jeremy Alexander, are attending the BONEZONE Magazine | OMTEC Expo conference in Chicago. They will be at the exhibition until close of business today – be sure to stop by booth #742 to say hello! #globalconsultancyservices #globalmedtech #ESTROT2024 #OMTEC2024 #pbcbiomed #acceleratingmedicalinnovation

That’s a wrap on this year’s Orthopedic Design & Technology Forum! Our team on the ground – Brittney Martinez and David Sharp, enjoyed a fantastic day of discussion, learning and opportunities to grow the PBC Biomed network in the US. This was our first time exhibiting at the event since we opened our Memphis office at the start of 2023 – it certainly will not be our last! If you missed Brittney and David at the event, please feel free to get in touch with us via email. Contact [email protected] for more information on our company, our people and what we do!

With an established track record of innovation, PBC BioMed has assembled a global team with a deep understanding of the regulatory, quality, clinical and commercial requirements facing innovators based in the EU or US, and wishing to enter new markets.

RCSI, MTU and PBC BioMed to collaborate on degenerative bone disease solution RCSI University of Medicine and Health Sciences, Munster Technological University and Irish SME, PBC BioMed are to collaborate on a medical device to address the degenerative bone disease, avascular necrosis. The project is supported by an Enterprise Ireland Innovation Partnership and will develop a bone scaffold that will support the re-growth and regeneration of the affected bone structure. The collaboration is based on patents held by PBC BioMed, tissue engineering and regenerative medicine expertise from the project lead in RCSI, Dr Orlaith Brennan and cell biology expertise in MTU from Dr Aleksandra Augustyniak. The current preferred treatment for avascular necrosis are bone grafts taken from the patient themselves. These can be painful, and the donor site can experience bone morbidity. This project is based on the development of scaffolds that are compatible with the body and have a similar microporous structure to bone. The scaffolds which contain compounds that stimulate development of new bone, will be placed at the site of the necrosis and as new bone formation is taking place, the scaffold slowly disintegrates, leaving behind strong, new bone. Dr Orlaith Brennan, RCSI said: This project offers an exciting opportunity for RCSI to collaborate with PBC BioMed and MTU to deliver patient-centred research which addresses a key international health challenge. The interest in tissue engineering and regenerative medicine as a viable alternative to bone grafts has been steadily gaining momentum and we look forward to developing this technology further. Dr Gerard Insley, Chief Scientific Officer, PBC Biomed, said ‘Avascular Necrosis is a silent bone disease which can lead to early joint replacement. This can be avoided or delayed and joint preservation achieved by addressing the biology of the diseased area. Extending the life of a joint by over five years using specifically engineered scaffolds through the creation of a biological chamber can enhance healing and bone repair’. Dr Aleksandra Augustyniak, MTU said: We’re really excited to secure this project, it is the First Innovation Partnership signed off as MTU so it’s a really historic moment for us. We’ve worked with PBC Biomed for some time and it’s a real step forward to get this substantial project funded.